FAK is known as an integrin-and growth factor-associated tyrosine kinase promoting cell motility. Here we show that, during mouse development, FAK inactivation results in p53-and p21-dependent mesodermal cell growth arrest. Reconstitution of primary FAK À/À p21 À/À fibroblasts revealed that FAK, in a kinase-independent manner, facilitates p53 turnover via enhanced Mdm2-dependent p53 ubiquitination. p53 inactivation by FAK required FAK FERM F1 lobe binding to p53, FERM F2 lobe-mediated nuclear localization, and FERM F3 lobe for connections to Mdm2 and proteasomal degradation. Staurosporine or loss of cell adhesion enhanced FERM-dependent FAK nuclear accumulation. In primary human cells, FAK knockdown raised p53-p21 levels and slowed cell proliferation but did not cause apoptosis. Notably, FAK knockdown plus cisplatin triggered p53-dependent cell apoptosis, which was rescued by either full-length FAK or FAK FERM re-expression. These studies define a scaffolding role for nuclear FAK in facilitating cell survival through enhanced p53 degradation under conditions of cellular stress.
INTRODUCTION
Integrins are transmembrane receptors that mediate cell attachment to ECM and also cooperate with growth factor receptors to generate intracellular signals regulating growth and survival. Disruption of these signals can trigger cell-cycle arrest or apoptosis (Gilmore, 2005) . One of the executioners of these events is the p53 tumor suppressor protein (Reddig and Juliano, 2005) . Under steady-state growth conditions, p53 expression is maintained at low levels via polyubiquitination and proteasomal degradation (Vousden, 2002) . Murine double minute-2 (Mdm2) is one of several ubiquitin E3 ligases that regulate p53 levels in cells (Iwakuma and Lozano, 2003) . Activation of p53 in response to stress signals is associated with increased p53 stability (Harris and Levine, 2005) leading to the enhanced transcription of targets such as p21Cip/WAF1 (p21) cyclin-dependent kinase inhibitor (Oren, 2003) . ECM-integrin signals can counteract p53 activation (Stromblad et al., 1996) and enhance proteasomal degradation of p21 (Bao et al., 2002) , but regulatory connections between integrins and p53 are not clear.
Focal adhesion kinase (FAK) and the related Pyk2 kinase are cytoplasmic tyrosine kinases activated by integrins and growth factor receptors (Parsons, 2003) . FAK inactivation during development yields an embryonic lethal phenotype, and the growth of FAK À/À fibroblasts and endothelial cells is facilitated by p53 inactivation (Ilic et al., , 1998 (Ilic et al., , 2003 . Although integrinstimulated FAK autophosphorylation at Y397, Src-family PTK binding to FAK pY397, and the formation of a FAK-Src signaling complex promote cell motility and cell survival, (Cox et al., 2006; Mitra and Schlaepfer, 2006) , the connections between FAK and p53 regulation remain loosely defined.
Recent studies have elucidated the structure of the FAK N-terminal band 4.1, ezrin, radixin, moesin homology (FERM) domain, which is comprised of three distinct lobes (F1, F2, and F3) (Lietha et al., 2007) and acts to regulate FAK kinase activity through an intramolecular inhibitory mechanism (Cohen and Guan, 2005; Lietha et al., 2007) . Interestingly, FAK can be modified by small ubiquitin-related modifier (SUMO) addition at K152 within the FERM domain (Kadare et al., 2003) , SUMOylated FAK is nuclear enriched, and exogenous FAK FERM expression is nuclear localized (Golubovskaya et al., 2005; Stewart et al., 2002) . Despite reports of FAK in the nucleus, the mechanism(s) that promotes or regulates FAK nuclear accumulation and the biological role of nuclear FAK remains unknown.
Here we show that loss of FAK activates p53 during mouse embryogenesis and that FAK À/À embryo cell proliferation ex vivo is made possible by either p53 or p21 inactivation. Although FAK has been proposed to inhibit p53 transcriptional activity (Golubovskaya et al., 2005) , we find that the MG132 proteosomal inhibitor blocks FAK regulation of p53. We show that FAK inactivates p53 in a kinase-independent manner via the FAK FERM domain acting as a scaffold to enhance Mdm2-dependent p53 ubiquitination. Although FERM domain SUMOylation is not required, p53 regulation is dependent on FAK nuclear translocation. Importantly, DNA damage-associated cell apoptosis could be rescued by wild-type (WT) but not nuclear-excluded FAK FERM re-expression after FAK knockdown in human fibroblasts. These results support a biological role for nuclear FAK in promoting cell proliferation and survival by facilitating p53 turnover.
RESULTS

Mesoderm Proliferation Defects in E8.5 FAK À/À
Mouse Embryos
The fak knockout results in an early embryonic lethal (E8.5) phenotype and size comparisons between normal FAK +/+ , FAK +/À , and FAK À/À littermates at E8.0-8.5
show that both FAK +/À and FAK À/À embryos are smaller than FAK +/+ embryos ( Figure 1A ). By E11.5, FAK +/À embryos become indistinguishable from FAK +/+ embryos, whereas FAK À/À embryos do not survive beyond E8.5-9.0 . To evaluate relative levels of cell proliferation during development, head-fold regions of FAK +/+ and FAK À/À littermate embryos were immunostained with antibodies to phosphorylated serine 10 histone H3 (pHis3) ( Figure 1B ). Equal numbers of pHis3-stained head-fold ectoderm cells were detected in FAK +/+ and FAK À/À embryos ( Figure 1C ). In contrast, few pHis3-stained mesoderm cells were detected in FAK À/À compared to FAK +/+ embryos ( Figures 1B and 1C ), supporting the notion that a proliferation defect induced by fak loss may occur in vivo.
p53 Accumulation Prevents FAK À/À Embryo
Proliferation Ex Vivo
To elucidate the potential role of p53 in FAK À/À embryo growth defects, we evaluated p53 protein levels in E8.5 embryo lysates ( Figure 1D ). During development, p53 protein is rapidly turned over and not normally detected before E10.5-11.0 (Gottlieb et al., 1997) . High levels of p53 and p53-responsive targets such as Mdm2 were detected in FAK À/À but not FAK +/+ embryos, suggestive of p53 activation in the absence of FAK ( Figure 1D ). , and FAK À/À E8.0-8.5 embryo lysates (Figure 2A ).
The upregulation of the FAK-related Pyk2 kinase was detected upon inactivation of one or both fak alleles. Comparisons of FAK +/+ and FAK À/À embryo lysates showed decreases in cyclin B and cyclin E and increases in cyclin-dependent kinase inhibitors p57(Kip2), p27(Kip1), and p21(Cip1) in the absence of FAK (Figure 2A ). These changes may reflect reduced cell proliferation within FAK À/À embryos; however, other cell-cycle-regulatory proteins such as p16(Ink4a) remained unchanged. In cell culture, p21 expression is enhanced by disruption of ECM-integrin linkages (Bao et al., 2002) and inhibited by FAK signaling (Bryant et al., 2006) . During embryogenesis, elevated p21 levels in the absence of FAK were dependent upon p53, as p21 expression was not detected in FAK Figure 2B ). To test whether elevated p21 levels contribute to the p53-dependent block in FAK À/À embryo cell proliferation, a p21 À/À mutation was introduced into a FAK 
p21
À/À cells, steady-state p53 levels were elevated, and transient FAK re-expression resulted in decreased p53 levels (see Figure S1A available online). This effect of FAK on p53 levels was associated with enhanced p53 turnover as determined by metabolic labeling of cells (Figures S1B-S1F).
To address which domains of FAK were required to promote p53 turnover, WT FAK or various FAK mutants ( Figure 3A) were re-expressed via adenovirus (Ad) in low-passage FAK À/À p21 À/À fibroblasts, and steady-state p53 levels were determined after 48 hr by anti-p53 blotting ( Figure 3B) . Surprisingly, WT FAK and various FAK signaling mutants functioned equally to reduce p53 levels by 60%-90% compared to mock-transduced cells ( Figure 3B ). Overexpression of the FAK C-terminal domain (termed FAK-related nonkinase, FRNK) slightly elevated p53 levels, whereas FAK residues 1-402 encompassing the FERM domain reduced p53 levels >80% ( Figure 3B ). As N-terminal truncated and activated FAK (D1-100) did not affect p53 levels and kinase-dead FAK decreased p53 levels ( Figure 3B ), our results support the notion that the FAK FERM domain plays a unique role in promoting p53 turnover in a kinase-independent manner.
p53 levels in cells are regulated by a balance between protein expression and degradation. Addition of MG132 proteasome inhibitor for 3 hr prior to cell lysis blocked FAK and FAK FERM effects on p53 ( Figure 3C ), supporting the conclusion that FAK FERM facilitates p53 turnover. To determine whether changes in p53 expression affect p53 transcriptional activity, a 2.4 kb region of the p21 promoter coupled to luciferase was used as a p53 activity reporter in FAK
À/À cells ( Figure 3D ). High p53 Figure 3F ). These results show that FAK FERM promotes p53 turnover through enhanced Mdm2-associated p53 ubiquitination and degradation.
FAK FERM F2 Lobe Facilitates FAK Nuclear Localization
As activated p53 is primarily nuclear localized and exogenous FAK FERM is nuclear enriched (Golubovskaya et al., 2005; Stewart et al., 2002) , analyses were undertaken to elucidate the determinants of FAK FERM nuclear targeting. Fusions of FAK residues (1-402) to green fluorescent protein (GFP) exhibit strong nuclear localization independent of Y397 phosphorylation ( Figure S2A ). The classic nuclear localization sequence typically contains clusters of basic amino acids. The avian FAK FERM domain is a three lobed (F1-F3) structure (Lietha et al., 2007) . Primary sequence alignments of the murine FAK FERM F2 lobe region showed that FAK and Pyk2 contained patches of basic amino acids that are not conserved in other FERM-containing proteins such as ezrin, radixin, moesin, or merlin ( Figure 4A ). Although these FAK F2 FERM domain basic residues are separated by primary sequence, they comprise surface-exposed clusters ( Figure 4B ). The largest patch consists of residues K190, K191, K216, K218, R221, and K222, whereas a second smaller basic patch is comprised of R204, R205, and K209. Residues R177 and R178 are partially exposed within the FAK FERM F2 lobe structure ( Figure 4B ). Alanine substitutions were introduced within the FAK FERM F2 lobe, and the effects on FAK FERM nuclear localization were monitored by fluorescence microscopy (data not shown) and cellular fractionation into nuclear (N) or cytosolic (C) extracts ( Figure 4C ). Mutations in the largest basic patch (K190/191A or K216/218A) blocked whereas mutations in a second smaller patch (K204/R205A) slightly reduced FERM nuclear accumulation. R177/R178A mutations also prevented FERM nuclear localization, whereas mutation of surface-exposed basic residues in the FAK FERM F3 lobe (R312/K313A) or the SUMOylation site (K152R) did not affect FERM nuclear targeting ( Figure 4C ). To prove the role of the FERM domain promoting FAK nuclear localization, GFP-FAK WT and GFP-FAK R177/R178A were expressed in FAK À/À fibroblasts or human umbilical endothelial cells (HUVECs) (data not shown) and GFP localization monitored by time-lapse imaging in the presence or absence of the nuclear export inhibitor leptomycin B ( Figure 4D ). In vehicle-treated cells, both FAK constructs were detected in focal contacts and the cytoplasm. Leptomycin B addition promoted WT but not FAK R177/R178A nuclear accumulation within 4 hr ( Figure 4D ). To analyze whether endogenous FAK is present in the nucleus, nuclear (N) or cytosolic (C) HUVEC extracts were analyzed for FAK distribution ( Figure 4E ). Approximately 5%-10% of HUVEC FAK is nuclear associated and tyrosine phosphorylated. To determine whether cellular stress may enhance FAK nuclear accumulation, HUVECs were treated with the protein kinase inhibitor staurosporine ( Figure 4F ). Within 30 min, staurosporine enhanced endogenous FAK and GFP-FAK but not FERM F2 lobe-mutated GFP-FAK R177/178A nuclear accumulation. This was accompanied by FAK dephosphorylation, loss of FAK from focal contacts, and preceded staurosporine-induced HUVEC apoptosis occurring within 4-8 hr (Figures S2B-S2F ). Staurosporine caused a rapid redistribution of GFP-FAK R177/ 178A from focal contacts to punctate cytoplasmic clusters, but not to the nucleus ( Figure S2E ). Loss of integrin-mediated cell adhesion is another cellular stressor, and this was also found to increase FAK nuclear accumulation within 30 min ( Figure 4G ). Together, these results support the importance of the FAK FERM F2 lobe in nuclear targeting. Moreover, the distribution of FAK at focal contacts, in the cytoplasm, or the nucleus is affected by cellular stress. fibroblasts were established. WT, K152R SUMOylation mutant, and R312/K313A FAK FERM F3 lobe-mutated proteins were nuclear localized, F2 lobe FERM mutants (R177/R178A and K190/K191A) were cytoplasmic distributed, and GFP-FRNK localized to focal contacts ( Figure 5A and Table S2 ). Steady-state p53 levels in FAK FERM-expressing cells were evaluated by immunoblotting and compared to parental FAK À/À p21 À/À and GFP-expressing controls. Cells expressing WT FERM and the SUMOylation (K152R) FERM mutant exhibited reduced p53 levels ( Figure 5B ). Importantly, mutations in the FERM F2 lobe (K190/ K191A and R177/R178A) blocked FAK FERM effects on lowering p53 levels ( Figure 5B ). However, mutations in the FAK FERM F3 lobe (R312/K313A) also blocked the ability of FAK FERM to reduce p53 levels ( Figure 5B ) even though R312/K313A FAK FERM was nuclear localized ( Figure 5A ). As p53 transcriptional activity paralleled p53 expression levels in FAK FERM-reconstituted FAK
À/À fibroblasts (data not shown), the combined results support the notion that FAK FERM nuclear localization is required, but not sufficient, for p53 regulation.
To determine whether full-length FAK modulates p53 activity in a similar manner as the FAK FERM, cotransfection assays were performed in FAK
À/À fibroblasts ( Figure 5C ). The p21 promoter-luciferase reporter was responsive to p53 reexpression resulting in $14-fold increased activity. Coexpression of WT or SUMOylation mutant K152R FAK resulted in >65% inhibition of p53 activity, whereas equal expression of F2 lobe-mutated R177/R178A FAK lowered p53 activity only 5%-10% ( Figure 5C ). F2 lobe-mutated K190/K191A or F3 lobe-mutated R312/K313A FAK only weakly inhibited p53 activity. Taken together, these results support the conclusion that prior to lysis, and GST (500 ng) or increasing amounts of recombinant GST-FAK (10-500 ng) were added prior to p53 isolation by IP. Bound Mdm2 and FAK within a p53 complex were detected by anti-HA and GST blotting.
FAK FERM F2 lobe-mediated nuclear translocation is important for p53 inhibition. However, the fact that FERM F3 lobe mutations (R312/K313A) did not affect nuclear translocation yet disrupted the ability of FAK to inhibit p53 indicates that FAK-mediated regulation of p53 involves multiple FERM-associated mechanisms.
FAK FERM Acts as a Scaffold to Facilitate p53 and Mdm2 Association
Coimmunoprecipitation (CoIP) analyses have shown that FAK and p53 can form a complex (Golubovskaya et al., 2005) , but the binding determinants for p53 within the FAK FERM domain remain unknown. GFP-FAK FERM or GFP-FRNK constructs were expressed in human A549 cells and evaluated for endogenous p53 association by CoIP analyses ( Figure 5D ). p53 associated with FAK FERM, but not FRNK, and p53 binding to FAK FERM was weakened by mutations in the F2 (R177/R178A), but not F3 (R312/K313A), lobes ( Figure 5D ). Similar results were obtained by GST-p53 pull-down assays ( Figure S3A ). Interestingly, F2 lobe-mutated K190/K191A FAK FERM can form a complex with p53 ( Figure 5D ), but these FERM mutations disrupt nuclear localization ( Figure 5A ) and p53 regulation (Figures 5B and 5C ). Additionally, F3 lobe-mutated R312/K313A FAK FERM localizes to the nucleus ( Figure 5A ) and binds to p53 ( Figure 5D ) but does not promote p53 turnover ( Figure 5B ). Together, these results support the notion that FERM-mediated nuclear localization, p53 binding, and FERM-enhanced p53 turnover are separable events. To determine whether individual FAK FERM lobes can associate with p53 or Mdm2 in cells, the F1, F2, or F3 regions were transiently expressed as GST fusion proteins in 293T cells ( Figures 5E and 5F ). The FAK FERM F1 lobe strongly associated with p53 in vivo, whereas weak binding was detected with FAK FERM F2 lobe, and no p53 binding was detected with the FAK FERM F3 lobe ( Figure 5E ). This result supports the notion that the FAK FERM p53 binding site likely spans the F1 and F2 FERM lobe regions. For Mdm2, FAK FERM F3 lobe bound the strongest, with only weak interactions detected with F1 or F2 FAK FERM lobes ( Figure 5F ). Interestingly, F3 lobe-mutated R311/K312A FERM bound Mdm2, and surprisingly, F2 lobe-mutated R177/R178A FERM exhibited enhanced Mdm2 binding ( Figure S3B ). Cotransfection studies revealed that both F2 and F3 lobe FERM mutations disrupted FAK FERM-enhanced p53 ubiquitination ( Figure 5G ) and support the notion that FAKenhanced p53 ubiquitination may be part of a nuclear-localized complex. Accordingly, although F2 lobe-mutated K190/K191 FERM can bind p53, this mutant is cytoplasmic distributed and fails to promote p53 ubiquitination. For F3 lobe-mutated R312/K313A FERM, it is likely that this mutation disrupts the binding of another protein other than Mdm2 that is needed to facilitate p53 ubiquitination.
To support the notion that FAK may act as a scaffold to enhance the formation of a p53-Mdm2 complex, FAK
fibroblasts were transfected with Flag-p53, HA-Mdm2, and increasing amounts of recombinant GST or GST-FAK added to cell lysates. A p53-Mdm2 association was detected in the absence of FAK, and this was not affected by purified GST addition ( Figure 5H ). GST-FAK addition increased the amount of p53-bound Mdm2 through the formation of a p53-Mdm2-FAK complex in a dose-dependent manner. However, excess GST-FAK did not enhance p53-Mdm2 complex formation even though increased GST-FAK bound to p53 ( Figure 5H ). This result is consistent with a biphasic scaffolding effect of FAK in facilitating p53 and Mdm2 interactions. Together with the FERM mutational results, these studies support the conclusion that nuclearlocalized FAK functions as a FERM-associated scaffold for p53 and Mdm2 binding that facilitates p53 ubiquitination leading to p53 turnover.
FAK Regulation of Cell Proliferation and p53-Dependent Apoptosis in Human Fibroblasts
As our studies support the importance of FAK in regulating p53 activation during development and in mouse fibroblasts, lentiviral-mediated FAK shRNA knockdown was used to test whether a FAK-p53 signaling axis exists in human fibroblasts and HUVECs. Within 72 hr, >80% of cells showed strong lentiviral GFP expression, and neither anti-FAK nor scrambled (Scr) shRNA expression promoted cell apoptosis ( Figure S4 ). However, >75% reduction in FAK expression was associated with $2-fold increased p53-p21 protein levels and reduced cell proliferation ( Figures 6A and 6B and Figure S5 ). To determine whether decreased FAK and elevated p53 levels would sensitize cells to DNA-damaging agents, Scr and FAK shRNA-expressing fibroblasts were treated with cisplatin. FAK shRNA cells showed $4-fold increased apoptosis compared to cisplatin-treated Scr shRNA cells (Figures 6C and 6D ) and the combination FAK shRNA plus cisplatin led to elevated p53 protein levels compared to cisplatin-treated Scr shRNA fibroblasts ( Figure 6E ).
To verify that increased cisplatin-stimulated apoptosis was due to decreased FAK, human fibroblasts were treated with FAK shRNA, and after 48 hr, cells were transduced with murine Ad-FAK WT or Ad-FAK D1-100 containing a deletion in the FAK FERM domain (Figures 6F and 6G ). This truncation of FAK activates FAK kinase activity and facilitates FAK signaling (Mitra and Schlaepfer, 2006) , but FAK D1-100 does not function to regulate p53 levels in mouse fibroblasts ( Figure 3B ). WT FAK re-expression blocked cisplatin-stimulated apoptosis in FAK shRNA cells, whereas D1-100 FAK had no effect ( Figure 6F ). Importantly, D1-100 FAK exhibited high activity levels as determined by antiphosphotyrosine blotting of fibroblast lysates and led to the robust activation of survival-associated signaling pathways such as Akt ( Figure 6G ). However, only WT FAK reduced p53 levels and prevented p21 expression in cisplatin-treated cells ( Figure 6G ). Importantly, cisplatin-stimulated apoptosis in FAK shRNA-expressing fibroblasts was dependent upon p53 as siRNA-mediated p53 reduction blocked both increased p21 expression and cell death ( Figures 6H and 6I) .
To prove the importance of the FAK FERM domain function in preventing cisplatin-stimulated apoptosis, cell survival analyses were performed after Ad-FERM WT or Ad-FERM R177/R178A expression in FAK shRNA knockdown human fibroblasts (Figures 6J and 6K ). FAK FERM, but not R177/178A FERM, blocked p53 accumulation, and only WT FAK FERM functioned to prevent apoptosis. These results are strong support for the biological importance of the FAK FERM domain in the regulation of p53-dependent cell survival. 
DISCUSSION
Null mutation of FAK results in an early embryonic lethal phenotype . Here, we show that fak inactivation is associated with the cessation of mesodermal cell proliferation and p53 activation during development. Interestingly, FAK null embryo ectoderm did not exhibit growth defects in vivo, and this may be due to different regulatory signals in epithelial versus mesodermal cells. However, as FAK null primary keratinocytes can proliferate in culture (Schober et al., 2007) , cells of ectodermal origin may have different or compensatory survival mechanisms compared to mesodermal fibroblasts. Interestingly, genetic inactivation of p53 or p21 in FAK null embryos did not rescue the embryonic lethal phenotype that remains associated with altered morphogenesis . However, loss of p53 or p21 enabled FAK À/À embryo cell proliferation ex vivo.
Thus, p53 activation induces cell-cycle arrest through p21 when FAK expression is impaired.
Unlike FAK, loss of other integrin-associated signaling proteins such as Src, p130Cas, paxillin, talin, or vinculin does not result in p53 activation or the blockage of primary fibroblast proliferation. Thus, FAK regulation of p53 during development is unlikely to involve canonical integrin signaling connections (Figure 7) . Moreover, FAK connections to p53 are conserved in primary human cells as FAK shRNA knockdown promotes increased p53/p21 levels accompanied by decreased cell proliferation. Interestingly, conditional inactivation of FAK in endothelial (Braren et al., 2006; Shen et al., 2005) or Schwann cells (Grove et al., 2007 ) is linked to apoptosis or decreased cell proliferation, respectively. This may be associated with p53 activation as primary FAK À/À endothelial cell proliferation was facilitated by p53 inactivation (Ilic et al., 2003) . kinase-associated signals have been shown to repress p21 expression (Bryant et al., 2006; Ding et al., 2005) , we found that kinase-inactive FAK functioned equally to WT FAK in repressing p53 expression using FAK À/À p21 À/À MEFs. Moreover, under stress induced by FAK knockdown combined with cisplatin addition to trigger p53 activation, re-expression of WT but not truncated (D1-100) FAK repressed p53/p21 expression and prevented p53-mediated apoptosis in human fibroblasts. Notably, D1-100 FAK was highly active and facilitated signals leading to Akt phosphorylation but did not function to promote survival. The inability of D1-100 FAK to counteract p53 activation is associated with the disruption of FERM domain function, as exogenous FAK FERM re-expression was sufficient to prevent cisplatin-stimulated apoptosis under FAK knockdown conditions.
To date, many studies have focused on the role of FAK kinaseassociated cell survival pathways indirectly through dominantnegative type experiments (Reddig and Juliano, 2005) . However, as a small molecule FAK catalytic inhibitor did not effect either normal or carcinoma cell proliferation or survival in culture (Slack-Davis et al., 2007) , these overexpression studies may need to be re-evaluated. As FAK functions as both a scaffold and signaling kinase, it is also difficult to distinguish the survival and proliferation alterations caused by the loss of FAK expression. Using a strategy of FAK re-expression within FAK À/À or FAK knockdown fibroblasts, our studies have identified the FAK FERM domain as the key module of a kinase-independent FAK-p53 regulatory cell survival circuit. Previously, FAK FERM domain overexpression has been shown to suppress apoptotic stimuli via interactions with the death domain kinase receptorinteracting protein (Kurenova et al., 2004) and indirectly implicated in the transcriptional inhibition of p53 via binding to the p53 transactivation domain (Golubovskaya et al., 2005) . Our studies support a different mode of p53 inhibition by FAK as proteasomal inhibitors prevent FAK inhibition of p53. We show that FAK inhibits p53 via FAK FERM nuclear translocation, FERM-mediated binding to p53, and FERM-enhanced Mdm2-dependent p53 ubiquitination (Figure 7 ).
Nuclear FAK, p53 Binding, and FERM-Enhanced p53 Degradation
The FAK FERM domain is comprised of three lobes (F1-F3) with similarity to other known FERM structures despite low primary sequence conservation (Lietha et al., 2007) . Through mutagenesis, biochemical cell fractionation, and confocal microscopy, we identified a patch of basic residues as a nuclear localization motif within the FAK FERM F2 lobe (K190, K191, K216, K218, and R221). These basic residues are separated by primary sequence, conserved between FAK and Pyk2, and not present in other FERM domain-containing proteins. As other F2 lobe (R177/R178A), but not F3 lobe (R312/K313A), FAK FERM mutations also disrupt FAK nuclear localization, correct F2 lobe FERM folding is also likely important for FAK nuclear targeting.
Coimmunoprecipitation analyses using the individual FAK FERM lobes revealed that the F1 lobe bound strongest to p53, whereas the F3 lobe bound to Mdm2 independent of p53 association. Overall, p53 inactivation by FAK required FAK FERM F1 lobe binding to p53, FERM F2 lobe-mediated nuclear localization, and FERM F3 lobe for connections to Mdm2 and proteasomal degradation. Importantly, mutations in the FERM F2 lobe (K190/K191A and R177/R178A) and within the FAK FERM F3 lobe (R312/K313A) blocked the ability of FAK FERM to reduce p53 levels. The mechanism or mechanisms associated with these mutational effects are likely distinct. F2 lobe R177/ R178A and K190/K191A FERM mutants can weakly bind p53, but they are cytoplasmically distributed and do not promote p53 ubiquitination. Even though F3 lobe-mutated R312/K313A FAK FERM was nuclear localized and can bind Mdm2, this mutation also disrupts the ability of FAK FERM to facilitate p53 ubiquitination. As FAK forms a multiprotein scaffolding complex with p53 and Mdm2 in a biphasic manner, we speculate that the presence of FAK in the nucleus acts to stabilize a p53-Mdm2 complex, leading to p53 polyubiquitination, and subsequent p53 degradation by nuclear or cytoplasmic proteasomes.
What conditions may promote FAK translocation to the nucleus? The nuclear export inhibitor leptomycin B promoted FAK nuclear accumulation in hours, whereas staurosporine treatment or loss of cell adhesion enhanced FAK nuclear distribution within 30 min. Nuclear FAK accumulation was also associated with a loss of FAK at focal contacts, and this supports the notion that there is a cytoplasmic pool of FAK that is free to shuttle in and out of the nucleus. We propose a model whereby, under conditions of cellular stress or reduced integrin signaling, the cytoplasmic pool of FAK is elevated, leading to increased FAK nuclear accumulation, which acts to enhance cell survival by facilitating p53 turnover. At present, the signals that regulate FAK cytoplasmic to nuclear movement remain undetermined. Although SUMOylated FAK was nuclear enriched (Kadare et al., 2003) , we found that K152 FAK SUMOylation was not essential for nuclear translocation. Interestingly, some transformed cell types can survive under suspension conditions, and this associated with reduced p53 activation (Lewis et al., 2002) . As FAK levels are elevated in many tumor cells (McLean et al., 2005) , and we find that FAK can form a complex with p53 in both normal and tumor cells, future studies will be aimed at determining whether this FAK-p53 cell survival pathway may also play a role in promoting tumor progression.
, and heterozygous FAK mice were housed and bred according to AALAC-approved institutional guidelines. Genomic DNA from placental cone and yolk sac were used for genotyping by PCR as described (Deng et al., 1995; Furuta et al., 1995; Tsukada et al., 1993) . Littermates from crossings of FAK +/À mice were dissected at E7.5 or E8.5, fixed briefly in 3.8% paraformaldehyde for 20 min, and embedded in OCT. Sections (5 mm) were stained with anti-phosphoserine-10 Histone3 (Upstate Biotech) and Hoechst 33342 (10 mg/ml, Molecular Probes) to identify proliferating cells.
Embryo Explant Culture E7.5-8.5 embryos were dissected from yolk sac and fetal membranes, placed in a drop of Matrigel (BD Biosciences), and cultured for 7 days in 10% FBS DMEM supplemented with 10 À4 M b-mercaptoethanol. To determine cell proliferation ex vivo, 10 mM BrdU was added to day 6 embryo explants. After 24 hr, embryos were disaggregated using trypsin and cells were plated in 10 mg/ml fibronectin-coated wells (Roche) in complete medium containing 10 mM BrdU for an additional 24 hr. Cells were fixed and stained with FITClabeled anti-BrdU antibody (Roche), and Hoechst 33342 (10 mg/ml) was added as a DNA counterstain. Data represent a minimum of five litters from mating of FAK-heterozygous mice on various genetic backgrounds.
Cells FAK
À/À p53 À/À and mouse embryonic fibroblasts (MEFs) were generated as described were generated by lentiviral infection and sorting for GFP. Lentiviral-associated GFP expression was removed by Ad-Cre transduction and verified by flow cytometry. Primary HUVECs were from Glycotech (Gaithersburg, MD).
Immunoblotting, Antibodies, and Chemicals E8.5 embryos were dissected from yolk sac and fetal membranes and then snap frozen. Five to ten embryos from three or more pregnant females were pooled together for each analysis. Embryos or cell lysates were made using modified RIPA buffer as described . Anti-FAK (4.47) and phosphotyrosine (4G10), Cyclin B1 (clone V152), and Cyclin E (07-687) were from Millipore. Mouse anti-HA (16B12), Myc-tag (9E10), and GFP (B34) were from Covance Research, and rat anti-HA tag (clone 3F10) was from Roche. Anti-b-actin (AC-17) and Flag-tag (M4) were from Sigma. Anti-Mdm2 (SMP-14), p21 (F-5), p16 Ink4a (F-12), p57 Kip2 (H-91), and p53 (DO-1) were from Santa Cruz. Anti-Pyk2 (clone 11), PARP (clone 42), and p27 Kip1 (clone 57) were from BD-Transduction. Anti-GAPDH (374, Chemicon), p53 (PAb240 and PAb122, Invitrogen), ubiquitin (FK-2, Biomol), pAkt (Ser-473, Cell Signaling Technology), and GST (30001, Pierce) were purchased. Anti-human p53 (CM1) and mouse p53 (CM5) were from Novocasta. Rabbit polyclonal anti-GFP was raised against recombinant 6-His-tagged-GFP produced from baculovirus culture. Affinity-purified anti-GFP antibodies were used for GFP-FAK FERM immunoprecipitation studies. ImageJ (1.36b) was used for densitometry and measurement of pixel intensity. Purified GST-FAK was from Active Motif. MG132, cisplatin, and staurosporine were from Calbiochem, and Leptomycin B was from LC Laboratories.
FAK Nuclear Localization and Subcellular Fractionation FAK
À/À p21 À/À MEFs expressing GFP-FAK FERM constructs were grown on glass coverslips coated with 0.1% gelatin, washed, fixed in 3.7% paraformaldehyde, and visualized by confocal microscopy (Bio-Rad Radiance 2100). FAK À/À p53 À/À MEFs expressing GFP-FAK WT or GFP-FAK R177/R178A mutants were grown on gelatin-coated glass coverslips in the presence or absence of leptomycin B (10 ng/ml) for 4 hr, fixed in 3.7% paraformaldehyde, and visualized at 603 using an inverted microscope (Olympus). Cellular fractionation studies were performed on transfected 293T cells and HUVECs in the absence or the presence of 1 mM staurosporine. After 48 hr, cells were washed in cold PBS and lysed with Cyt buffer (10 mM Tris [pH 7.5], 0.05% NP-40, 3 mM MgCl 2 , 100 mM NaCl, 1 mM EGTA, 20 mg/ml aprotinin, 1 mM orthovanadate, and 10 mg/ml leupeptin). Cells were scrape loaded into tubes, incubated for 5 min at 4 C, spun at 800 3 g at 4 C (5 min), and cytosolic supernatants collected. Cell pellets were further washed with cyto buffer twice to remove residual cytosolic proteins. Purified nuclei were resuspended in RIPA buffer, spun at 16,000 3 g for 15 min, and supernatant collected as the nuclear fraction. Samples were separated by SDS-PAGE and immunoblotted for gylceraldehyde-3-phosphate dehydrogenase (GAPDH) and poly ADPribose polymerase (PARP) as cytoplasmic and nuclear markers, respectively.
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